Edition:
United States

Bristol-Myers Squibb Co (BMY.N)

BMY.N on New York Stock Exchange

62.93USD
19 Sep 2017
Change (% chg)

$0.23 (+0.37%)
Prev Close
$62.70
Open
$62.70
Day's High
$63.12
Day's Low
$62.59
Volume
1,076,991
Avg. Vol
1,834,472
52-wk High
$63.46
52-wk Low
$46.01

Latest Key Developments (Source: Significant Developments)

Bristol-Myers Squibb and Halozyme enter global collaboration and license agreement for enhanze technology
Thursday, 14 Sep 2017 06:59am EDT 

Sept 14 (Reuters) - Bristol-Myers Squibb Co :Bristol-Myers Squibb and Halozyme enter global collaboration and license agreement for enhanze technology.Bristol-Myers Squibb Co - ‍Halozyme to receive $105 million upfront payment, plus future milestones and royalties​.Bristol-Myers Squibb Co - ‍Halozyme to receive $105 million upfront payment, plus future milestones and royalties​.Bristol-Myers Squibb Co - ‍provides Bristol-Myers Squibb access to enhanze technology for up to 11 targets​.Bristol-Myers Squibb Co - ‍collaboration may extend to a maximum of 11 targets​.Bristol-Myers Squibb Co - ‍for Bristol-Myers Squibb, transaction is expected to be dilutive to non-gaap earnings per share in 2017​.Bristol-Myers - ‍Halozyme has potential to earn milestone payments of upto $160 million for each nominated collaboration targets,additional milestone payments​.Bristol-Myers Squibb says ‍for co, deal is expected to be dilutive to non-GAAP earnings per share in 2017 and 2018 by approximately $0.01​.Bristol-Myers Squibb Co - ‍for co, deal is expected to be dilutive to non-GAAP earnings per share by about $0.05 in 2019​.  Full Article

Bristol-Myers Squibb Co says ‍declared a quarterly dividend
Wednesday, 13 Sep 2017 04:30pm EDT 

Sept 13 (Reuters) - Bristol-myers Squibb Co :Bristol-Myers Squibb Co - ‍declared a quarterly dividend of thirty-nine cents ($0.39) per share on $.10 par value common stock of corporation​.  Full Article

Heat Biologics been granted type C meeting with FDA
Tuesday, 12 Sep 2017 07:40am EDT 

Sept 12 (Reuters) - Heat Biologics Inc ::Heat Biologics- ‍been granted type C meeting with FDA; to discuss registrational pathway for non-small cell lung cancer trial with HS-110 in combination with Bristol Myers' opdivo.  Full Article

Transgene says U.S. FDA grants IND clearance to Phase 2 trial of TG4010 in combination with Opdivo
Monday, 11 Sep 2017 11:46am EDT 

Sept 11 (Reuters) - Transgene SA ::Receives FDA IND approval to begin a clinical trial with TG4010 + Nivolumab + Chemotherapy in the first-line treatment of Lung Cancer (NSCLC).‍Phase 2 clinical trial is in collaboration with Bristol-Myers Squibb​.First patient expected to be enrolled at end of 2017.  Full Article

Bristol-Myers Squibb says ‍two opdivo trials show 3-year survival benefit
Friday, 8 Sep 2017 05:30am EDT 

Sept 8 (Reuters) - Bristol-Myers Squibb Co ::Bristol-Myers Squibb - ‍two pivotal opdivo trials show 3-year survival benefit in patients with previously treated advanced non-small cell lung cancer​.Bristol-Myers Squibb Co - ‍results represent longest phase 3 follow-up data reported for a PD-1 inhibitor in second-line non-small cell lung cancer​.Bristol-Myers Squibb-‍data continued to show benefit with opdivo in overall population, with nearly triple, double patients alive at 3 years versus docetaxel​.  Full Article

‍Bristol-Myers Squibb says Opdivo plus Yervoy showed superior overall survival
Thursday, 7 Sep 2017 06:59am EDT 

Sept 7 (Reuters) - Bristol-Myers Squibb Co :Checkmate-214 study evaluating Opdivo in combination with Yervoy stopped early for demonstrating overall survival benefit in patients with previously untreated advanced or metastatic renal cell carcinoma.Combination of Opdivo and Yervoy also met secondary endpoint of improved overall survival in all randomized patients​.Opdivo plus Yervoy showed superior overall survival versus current standard of care Sunitinib in intermediate- poor-risk patients.Based on planned interim analysis, independent data monitoring committee recommended that trial be stopped early for Opdivo​.  Full Article

Bristol-Myers Squibb to acquire IFM Therapeutics to strengthen oncology pipeline focus on innate immunity
Thursday, 3 Aug 2017 04:00pm EDT 

Aug 3 (Reuters) - Bristol-Myers Squibb Co :Bristol-Myers Squibb to acquire IFM Therapeutics to strengthen oncology pipeline focus on innate immunity.Bristol-Myers Squibb to acquire IFM Therapeutics to strengthen oncology pipeline focus on innate immunity.Bristol-Myers Squibb Co - ‍IFM Therapeutics to receive $300 million upfront​.Bristol-Myers Squibb Co - deal includes potential of up to $1.01 billion in milestones for each of first products from two programs​.Says ‍IFM is eligible for additional contingent milestone payments for further products resulting from these programs​.Bristol-Myers - gains full rights to IFM's preclinical sting, nlrp3 agonist programs focused on enhancing innate immune response for treating cancer​.Bristol-Myers Squibb Co - ‍transaction has been approved by boards of directors of both companies and by stockholders of ifm​.Says ‍newly formed entity will be established by current shareholders of IFM - IFM Therapeutics LLC​.  Full Article

Seattle Genetics to buy Bothell plant from Bristol-Myers Squibb
Tuesday, 1 Aug 2017 04:00pm EDT 

Aug 1 (Reuters) - Bristol-Myers Squibb Co :Seattle Genetics announces purchase of Bothell manufacturing facility from Bristol-Myers Squibb.Seattle Genetics - ‍signed definitive agreements to purchase Bristol-Myers Squibb's pharmaceutical manufacturing facility in Bothell, Washington​.Seattle Genetics - ‍intends to offer employment to manufacturing facility's current employees​.Seattle Genetics - plans to utilize facility primarily for antibody production for current and future pipeline programs​.Seattle Genetics - ‍company intends to offer employment to manufacturing facility's current employees​.  Full Article

Bristol-Myers Squibb receives FDA approval for opdivo
Tuesday, 1 Aug 2017 06:59am EDT 

Aug 1 (Reuters) - Bristol-myers Squibb Co ::Bristol-Myers Squibb receives FDA approval for opdivo (nivolumab) in MSI-H or DMMR metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.Bristol-Myers Squibb receives FDA approval for opdivo (nivolumab) in MSI-H or DMMR metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.  Full Article

Bristol-Myers, Clovis Oncology announce broad clinical collaboration
Monday, 31 Jul 2017 06:59am EDT 

July 31 (Reuters) - Bristol-Myers Squibb Co ::Bristol-Myers Squibb and Clovis Oncology announce a broad clinical collaboration to evaluate combination of opdivo (nivolumab) and rubraca (rucaparib) in phase 2 and pivotal phase 3 clinical trials in multiple tumor types.Bristol-Myers Squibb Co says specific terms of agreement were not disclosed.Bristol-Myers Squibb Co - specific terms of agreement were not disclosed.Bristol-Myers Squibb Co - ‍all three studies are expected to begin before end of 2017​.Bristol-Myers Squibb - phase 2 trial to evaluate opdivo in combination with rubraca, other compounds in metastatic castration-resistant prostate cancer.Bristol-Myers Squibb Co says planned multi-arm clinical trials will be conducted in U.S., Europe, and possibly additional countries.Bristol-Myers Squibb - phase 3 trials planned for 2017 will evaluate rubraca in combination with opdivo, rubraca as monotherapy, & opdivo as monotherapy.Bristol-Myers Squibb Co - ‍clovis will be study sponsor and conducting party for ovarian cancer study​.Bristol-Myers Squibb - collaboration will also include phase 2 study to evaluate safety and efficacy of opdivo in combination with rubraca.  Full Article

Photo

UK backs Opdivo for lung cancer after Bristol-Myers cuts price

LONDON Bristol-Myers Squibb's immunotherapy drug Opdivo has been recommended for some patients with lung cancer by Britain's healthcare cost watchdog NICE after the drugmaker agreed a discounted price.